Immediate Management of Severe Hyperglycemia on Mixtard
Increase the evening Mixtard dose by 10-20% (add 3-6 units to the current 32 units) and assess for symptoms of hyperglycemia that may warrant immediate medical evaluation.
Immediate Assessment
First, determine if this patient requires urgent intervention:
- Check for symptoms of severe hyperglycemia: polyuria, polydipsia, altered mental status, signs of diabetic ketoacidosis (DKA), or hyperosmolar hyperglycemic state
- If symptomatic or glucose consistently >300 mg/dL with A1C >10%, consider hospitalization for IV insulin therapy 1
- If asymptomatic, proceed with outpatient dose adjustment
Dose Adjustment Strategy
The evening glucose of 436 mg/dL indicates inadequate overnight basal coverage from the evening Mixtard dose. The afternoon reading of 340 mg/dL suggests inadequate coverage from the morning dose as well.
Primary Adjustment (Evening Dose):
- Increase evening Mixtard from 32 to 35-38 units (10-20% increase) 1
- The evening dose primarily controls overnight and fasting glucose, which is clearly inadequate given the 436 mg/dL reading
Secondary Adjustment (Morning Dose):
- Increase morning Mixtard from 36 to 40-43 units (10-20% increase) 1
- This addresses the afternoon hyperglycemia of 340 mg/dL
Titration Schedule:
- Adjust doses every 2-3 days based on glucose patterns 2
- Continue increasing by 10-20% until glucose levels are <180 mg/dL 3, 4
Important Caveats
Mixtard is a premixed insulin (30% regular/70% NPH), which limits flexibility compared to basal-bolus regimens. Consider these issues:
- Risk of hypoglycemia: The short-acting component peaks 2-4 hours post-injection, so ensure adequate meal intake
- If hypoglycemia occurs: Reduce the corresponding dose by 10-20% 1
- Assess meal patterns: Mixtard requires consistent carbohydrate intake at meals; irregular eating increases hypoglycemia risk
When to Consider Regimen Change
If glucose remains >180 mg/dL despite dose increases to 40+ units twice daily, strongly consider switching to a basal-bolus regimen with long-acting basal insulin (glargine or detemir) plus rapid-acting prandial insulin 1, 5. This provides:
- Better physiologic insulin coverage
- More flexibility with meal timing
- Lower hypoglycemia risk compared to NPH-based regimens 5
Monitoring Requirements
- Check fasting glucose daily to assess evening dose adequacy
- Check pre-dinner glucose to assess morning dose adequacy
- Check A1C if not done recently to guide overall treatment intensity 1
- Monitor for hypoglycemia symptoms, especially 2-4 hours after injections
Additional Considerations
If A1C remains elevated despite insulin optimization, consider adding:
- GLP-1 receptor agonist for additional glucose lowering and weight benefit 1
- SGLT2 inhibitor if cardiovascular or kidney disease present 1
Do not use sliding-scale insulin alone - it is ineffective and excludes necessary basal coverage 5, 6.